Biofrontera AG (XETRA: B8F.DE) Stock Competitors & Peer Comparison
See B8F.DE's competitors and their performance on the XETRA and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for B8F.DE and its XETRA peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| B8F.DE | €6.80 | +2000.00% | 20.7M | -32.40 | -€0.21 | N/A |
| MRK.DE | €138.40 | +0.25% | 59.9B | 16.42 | €8.40 | +1.59% |
| ZOE.DE | €65.68 | +0.46% | 27.9B | 11.90 | €5.59 | +2.68% |
| 5EA.DE | €20.68 | +2.71% | 10.2B | -50.21 | -€0.41 | N/A |
| DMP.DE | €39.80 | -0.25% | 2B | 14.77 | €2.72 | +2.19% |
| EVT.DE | €3.27 | -2.56% | 596.1M | -3.06 | -€1.10 | N/A |
| 2HQ0.DE | €4.05 | +1.76% | 461.3M | -7.60 | -€0.54 | N/A |
| PSG.DE | €29.00 | +0.00% | 333.9M | 17.26 | €1.68 | N/A |
| HAEK.DE | €21.40 | -1.83% | 111.5M | 11.57 | €1.85 | N/A |
| APPH.DE | €11.00 | +0.00% | 91.6M | 137.50 | €0.08 | N/A |
Stock Comparison
Merck KGaA (XETRA: MRK.DE)
B8F.DE vs MRK.DE Comparison August 2026
Biofrontera AG (XETRA: B8F.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, B8F.DE stands at 20.7M. In comparison, MRK.DE has a market cap of 59.9B. Regarding current trading prices, B8F.DE is priced at €6.80 on the XETRA, while MRK.DE trades at €138.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
B8F.DE currently has a P/E ratio of -32.40, whereas MRK.DE's P/E ratio is 16.42. In terms of profitability, B8F.DE's ROE is -0.02%, compared to MRK.DE's ROE of +0.08%. Regarding short-term risk, B8F.DE is more volatile compared to MRK.DE. This indicates higher risk in terms of short-term price fluctuations for B8F.DE.Check MRK.DE's competition here
Zoetis Inc. (XETRA: ZOE.DE)
B8F.DE vs ZOE.DE Comparison August 2026
Biofrontera AG (XETRA: B8F.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, B8F.DE stands at 20.7M. In comparison, ZOE.DE has a market cap of 27.9B. Regarding current trading prices, B8F.DE is priced at €6.80 on the XETRA, while ZOE.DE trades at €65.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
B8F.DE currently has a P/E ratio of -32.40, whereas ZOE.DE's P/E ratio is 11.90. In terms of profitability, B8F.DE's ROE is -0.02%, compared to ZOE.DE's ROE of +0.69%. Regarding short-term risk, B8F.DE is more volatile compared to ZOE.DE. This indicates higher risk in terms of short-term price fluctuations for B8F.DE.Check ZOE.DE's competition here
Elanco Animal Health, Inc. (XETRA: 5EA.DE)
B8F.DE vs 5EA.DE Comparison August 2026
Biofrontera AG (XETRA: B8F.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, B8F.DE stands at 20.7M. In comparison, 5EA.DE has a market cap of 10.2B. Regarding current trading prices, B8F.DE is priced at €6.80 on the XETRA, while 5EA.DE trades at €20.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
B8F.DE currently has a P/E ratio of -32.40, whereas 5EA.DE's P/E ratio is -50.21. In terms of profitability, B8F.DE's ROE is -0.02%, compared to 5EA.DE's ROE of -0.03%. Regarding short-term risk, B8F.DE is more volatile compared to 5EA.DE. This indicates higher risk in terms of short-term price fluctuations for B8F.DE.Check 5EA.DE's competition here
Dermapharm Holding SE (XETRA: DMP.DE)
B8F.DE vs DMP.DE Comparison August 2026
Biofrontera AG (XETRA: B8F.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, B8F.DE stands at 20.7M. In comparison, DMP.DE has a market cap of 2B. Regarding current trading prices, B8F.DE is priced at €6.80 on the XETRA, while DMP.DE trades at €39.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
B8F.DE currently has a P/E ratio of -32.40, whereas DMP.DE's P/E ratio is 14.77. In terms of profitability, B8F.DE's ROE is -0.02%, compared to DMP.DE's ROE of +0.21%. Regarding short-term risk, B8F.DE is more volatile compared to DMP.DE. This indicates higher risk in terms of short-term price fluctuations for B8F.DE.Check DMP.DE's competition here
Evotec SE (XETRA: EVT.DE)
B8F.DE vs EVT.DE Comparison August 2026
Biofrontera AG (XETRA: B8F.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, B8F.DE stands at 20.7M. In comparison, EVT.DE has a market cap of 596.1M. Regarding current trading prices, B8F.DE is priced at €6.80 on the XETRA, while EVT.DE trades at €3.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
B8F.DE currently has a P/E ratio of -32.40, whereas EVT.DE's P/E ratio is -3.06. In terms of profitability, B8F.DE's ROE is -0.02%, compared to EVT.DE's ROE of -0.26%. Regarding short-term risk, B8F.DE is more volatile compared to EVT.DE. This indicates higher risk in terms of short-term price fluctuations for B8F.DE.Check EVT.DE's competition here
Tilray Brands, Inc. (XETRA: 2HQ0.DE)
B8F.DE vs 2HQ0.DE Comparison August 2026
Biofrontera AG (XETRA: B8F.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, B8F.DE stands at 20.7M. In comparison, 2HQ0.DE has a market cap of 461.3M. Regarding current trading prices, B8F.DE is priced at €6.80 on the XETRA, while 2HQ0.DE trades at €4.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
B8F.DE currently has a P/E ratio of -32.40, whereas 2HQ0.DE's P/E ratio is -7.60. In terms of profitability, B8F.DE's ROE is -0.02%, compared to 2HQ0.DE's ROE of -0.08%. Regarding short-term risk, B8F.DE is more volatile compared to 2HQ0.DE. This indicates higher risk in terms of short-term price fluctuations for B8F.DE.Check 2HQ0.DE's competition here
PharmaSGP Holding SE (XETRA: PSG.DE)
B8F.DE vs PSG.DE Comparison August 2026
Biofrontera AG (XETRA: B8F.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, B8F.DE stands at 20.7M. In comparison, PSG.DE has a market cap of 333.9M. Regarding current trading prices, B8F.DE is priced at €6.80 on the XETRA, while PSG.DE trades at €29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
B8F.DE currently has a P/E ratio of -32.40, whereas PSG.DE's P/E ratio is 17.26. In terms of profitability, B8F.DE's ROE is -0.02%, compared to PSG.DE's ROE of +0.54%. Regarding short-term risk, B8F.DE is more volatile compared to PSG.DE. This indicates higher risk in terms of short-term price fluctuations for B8F.DE.Check PSG.DE's competition here
Haemato AG (XETRA: HAEK.DE)
B8F.DE vs HAEK.DE Comparison August 2026
Biofrontera AG (XETRA: B8F.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, B8F.DE stands at 20.7M. In comparison, HAEK.DE has a market cap of 111.5M. Regarding current trading prices, B8F.DE is priced at €6.80 on the XETRA, while HAEK.DE trades at €21.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
B8F.DE currently has a P/E ratio of -32.40, whereas HAEK.DE's P/E ratio is 11.57. In terms of profitability, B8F.DE's ROE is -0.02%, compared to HAEK.DE's ROE of +0.06%. Regarding short-term risk, B8F.DE is more volatile compared to HAEK.DE. This indicates higher risk in terms of short-term price fluctuations for B8F.DE.Check HAEK.DE's competition here
Apontis Pharma AG (XETRA: APPH.DE)
B8F.DE vs APPH.DE Comparison August 2026
Biofrontera AG (XETRA: B8F.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, B8F.DE stands at 20.7M. In comparison, APPH.DE has a market cap of 91.6M. Regarding current trading prices, B8F.DE is priced at €6.80 on the XETRA, while APPH.DE trades at €11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
B8F.DE currently has a P/E ratio of -32.40, whereas APPH.DE's P/E ratio is 137.50. In terms of profitability, B8F.DE's ROE is -0.02%, compared to APPH.DE's ROE of +0.02%. Regarding short-term risk, B8F.DE is more volatile compared to APPH.DE. This indicates higher risk in terms of short-term price fluctuations for B8F.DE.Check APPH.DE's competition here
Tilray Brands, Inc. (XETRA: 2HQ.DE)
B8F.DE vs 2HQ.DE Comparison August 2026
Biofrontera AG (XETRA: B8F.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, B8F.DE stands at 20.7M. In comparison, 2HQ.DE has a market cap of 78.9M. Regarding current trading prices, B8F.DE is priced at €6.80 on the XETRA, while 2HQ.DE trades at €0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
B8F.DE currently has a P/E ratio of -32.40, whereas 2HQ.DE's P/E ratio is -0.66. In terms of profitability, B8F.DE's ROE is -0.02%, compared to 2HQ.DE's ROE of -1.15%. Regarding short-term risk, B8F.DE is more volatile compared to 2HQ.DE. This indicates higher risk in terms of short-term price fluctuations for B8F.DE.Check 2HQ.DE's competition here
SynBiotic SE (XETRA: SBX.DE)
B8F.DE vs SBX.DE Comparison August 2026
Biofrontera AG (XETRA: B8F.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, B8F.DE stands at 20.7M. In comparison, SBX.DE has a market cap of 3.6M. Regarding current trading prices, B8F.DE is priced at €6.80 on the XETRA, while SBX.DE trades at €0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
B8F.DE currently has a P/E ratio of -32.40, whereas SBX.DE's P/E ratio is -0.30. In terms of profitability, B8F.DE's ROE is -0.02%, compared to SBX.DE's ROE of -0.55%. Regarding short-term risk, B8F.DE is more volatile compared to SBX.DE. This indicates higher risk in terms of short-term price fluctuations for B8F.DE.Check SBX.DE's competition here
Paion AG (XETRA: PA8.DE)
B8F.DE vs PA8.DE Comparison August 2026
Biofrontera AG (XETRA: B8F.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, B8F.DE stands at 20.7M. In comparison, PA8.DE has a market cap of 2.7M. Regarding current trading prices, B8F.DE is priced at €6.80 on the XETRA, while PA8.DE trades at €0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
B8F.DE currently has a P/E ratio of -32.40, whereas PA8.DE's P/E ratio is -0.13. In terms of profitability, B8F.DE's ROE is -0.02%, compared to PA8.DE's ROE of -0.09%. Regarding short-term risk, B8F.DE is more volatile compared to PA8.DE. This indicates higher risk in terms of short-term price fluctuations for B8F.DE.Check PA8.DE's competition here
XPhyto Therapeutics Corp. (XETRA: 4XT.DE)
B8F.DE vs 4XT.DE Comparison August 2026
Biofrontera AG (XETRA: B8F.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, B8F.DE stands at 20.7M. In comparison, 4XT.DE has a market cap of 0. Regarding current trading prices, B8F.DE is priced at €6.80 on the XETRA, while 4XT.DE trades at €0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
B8F.DE currently has a P/E ratio of -32.40, whereas 4XT.DE's P/E ratio is -2.18. In terms of profitability, B8F.DE's ROE is -0.02%, compared to 4XT.DE's ROE of -7.27%. Regarding short-term risk, B8F.DE is more volatile compared to 4XT.DE. This indicates higher risk in terms of short-term price fluctuations for B8F.DE.Check 4XT.DE's competition here
Mallinckrodt plc (XETRA: MCD.DE)
B8F.DE vs MCD.DE Comparison August 2026
Biofrontera AG (XETRA: B8F.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, B8F.DE stands at 20.7M. In comparison, MCD.DE has a market cap of 0. Regarding current trading prices, B8F.DE is priced at €6.80 on the XETRA, while MCD.DE trades at €0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
B8F.DE currently has a P/E ratio of -32.40, whereas MCD.DE's P/E ratio is -0.02. In terms of profitability, B8F.DE's ROE is -0.02%, compared to MCD.DE's ROE of -1.69%. Regarding short-term risk, B8F.DE is more volatile compared to MCD.DE. This indicates higher risk in terms of short-term price fluctuations for B8F.DE.Check MCD.DE's competition here